Incorporation of obidoxime into human serum albumin nanoparticles: optimisation of preparation parameters for the development of a stable formulation.
Intoxication with organophosphorous nerve agents such as paraoxon requires immediate administration of antidotes such as oximes. However, the oximes lack sufficient activity in the central nervous system as they are unable to rapidly penetrate the blood-brain barrier (BBB) in therapeutically relevant concentrations. Human serum albumin (HSA) nanoparticles represent a promising drug carrier system for the transport of drugs across the BBB. This study focussed on the development of an obidoxime-loaded nanoparticles prepared by desolvation using an incorporation technique. The nanoparticle preparation parameters, i.e. drug amount, pH value, ethanol volume and crosslinking degree, were optimised. The in vitro release study showed a sustained release profile, indicating the suitability of the developed formulation for the transport of oximes across the BBB.